Month: January 2022

Release – CanAlaska Deals Further Three Uranium Projects for AUD$15M

Posted on by Admin



CanAlaska Deals Further Three Uranium Projects for AUD$15M

Research, News, and Market Data on CanAlaska Uranium

 

Basin Energy has Staged Option to Earn up to 80% Interest in Two Properties and Additional Option to Earn up to 100% in One Property

Focus on High-Grade Eastern Athabasca Basement and Unconformity Uranium Targets

Vancouver, Canada, January 26, 2022 – CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) is pleased to announce it has entered into a Letter of Intent (“LOI”) with Basin Energy Limited (“Basin Energy”), an Australian unlisted public company, to allow Basin Energy to earn up to an 80% interest in CanAlaska’s 100%-owned North Millennium and Geikie projects, and a 100% interest in CanAlaska’s 100%-owned Marshall project. These projects total 50,994.56 hectares in the Eastern Athabasca Basin in Saskatchewan, Canada (the “Projects”) (Figure 1).

North Millennium and Geikie Projects

Basin Energy may earn up to an 80% interest in each of the North Millennium and Geikie projects by undertaking work and milestone payments in three defined earn-in stages on each project.

  • Basin Energy may earn an initial 40% interest (“40% Option”) in each of the projects by paying the Company AUD$41,666.66 cash per project and issuing 6.66% worth of ordinary shares in Basin Energy’s capital structure as at listing on the Australian Securities Exchange (“ASX”) per project within 180 days following execution of a definitive Property Option Agreement (“POA”). Basin Energy will have the right to extend the 40% Option on a month-by-month basis for up to three (3) consecutive months upon payment of an option extension fee of AUD$8,333 per month per project.
  • Basin Energy may earn an additional 20% interest (“60% Option”) in each of the projects by incurring AUD$2,500,000 in exploration expenditures per project within 24 months of the ASX listing date.
  • Basin Energy may earn an additional 20% interest (“80% Option”) in each of the projects by issuing a further 2,250,000 ordinary shares in Basin Energy per project and incurring an additional AUD$5,000,000 (total: AUD$7,500,000) in exploration expenditures per project within 48 months of the ASX listing date and granting the Company a 2.75% net smelter returns (“NSR”) royalty on all products derived from the claims with a repurchase right of 0.50% NSR for AUD$500,000 at any time commencing from the grant of the 2.75% NSR per project.
  • CanAlaska will be operator of the projects through the 60% Option threshold and charge an operator fee.
  • Basin Energy will be obligated to keep and maintain the North Millennium and Geikie claims in good standing for a minimum period of one year at all times during the term of the POA.
  • A Joint Technical Operating Committee (“JTOC”) will be established. Basin Energy will have the deciding vote on all expenditures to be incurred on the claims during the term of the POA.

After successful completion of either of the 40% Option or 60% Option stages of the agreement, and if Basin Energy elects to not enter the final stage, a joint venture will be formed and the parties will co-contribute on a simple pro-rata basis or dilute on a pre-defined straight-line dilution formula. If either party dilutes to a 10% interest, the diluting party will automatically forfeit its interest in the respective project and in lieu thereof will be granted a 2.75% net smelter returns (NSR) royalty on the respective property on all products derived from the claims with a repurchase right of 0.50% NSR for AUD$500,000 at any time commencing from the grant of the 2.75% NSR, except that, this provision will not apply to CanAlaska if CanAlaska has already been granted the 2.75% NSR prior to diluting to a 10% interest.

An area of mutual interest will be established that extends two kilometres from the boundary of the claims.

 

Marshall Project

Basin Energy may acquire a 100% interest in the Marshall project by:

  • Paying the Company AUD$41,666.66 cash and issuing 6.66% worth of ordinary shares in Basin Energy’s capital structure as at listing on the ASX within 180 days following execution of a definitive POA. Basin Energy will have the right to extend the payment period on a month-by-month basis for up to three (3) consecutive months upon payment of an option extension fee of AUD$8,333 per month.
  • Granting to the Company a 2.75% net smelter returns (“NSR”) royalty on all products derived from the claims with a repurchase right of 0.50% NSR for AUD$500,000 at any time commencing from the grant of the 2.75% NSR.
  • CanAlaska and Basin Energy will enter into an agreement, on terms acceptable to both parties, pursuant to which Basin Energy will engage the Company to be the operator of the initial AUD$1,500,000 work program on the property after closing of the transaction. CanAlaska will be entitled to charge Basin Energy an operator fee.

 

About Basin Energy Limited

Basin Energy Limited (ACN 655 515 110) is an Australian unlisted uranium exploration and development company incorporated for the purpose of pursuing highly prospective uranium opportunities globally. It is a condition of completion of this transaction that Basin Energy be listed on the ASX.

CanAlaska CEO, Cory Belyk, comments, “CanAlaska is very pleased to work with Basin Energy, another pending Australian-listed player in the Athabasca Basin, to help fund the next stages of exploration on these new and highly prospective Eastern Athabasca uranium projects we staked in 2021. This very significant investment by Basin Energy is another example of CanAlaska’s project generator model at work that will allow for discovery opportunities for our shareholders without dilution in our core Eastern Athabasca projects.”

 

Other News

The Company is currently drilling on its Waterbury South project near the Cigar Lake mine.

 

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 300,000 hectares (750,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.”  CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds.

For further information visit www.canalaska.com.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: info@canalaska.com

Cory Belyk, CEO and Executive Vice President
Tel: +1.604.688.3211 x 138
Email: cbelyk@canalaska.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Release – BioSig Awarded US Patent Claims for its PURE EP Noise-Filtering Technology

Posted on by Admin



BioSig Awarded US Patent Claims for its PURE EP™ Noise-Filtering Technology

News and Market Data on BioSig Technologies

 

Westport, CT, Jan. 26, 2022 (GLOBE NEWSWIRE) —

  • Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP™ technology
  • The Company now has 49 issued or allowed worldwide patents covering its novel technology for arrhythmia care

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the US Patent Office had allowed a utility patent covering its PURE EP™ noise-filtering technology. The recently allowed patent application number 17/091,357 entitled “Universal Notch Filter“ was filed on November 6, 2020. The patent describes and claims computer-implemented methods for filtering noise from an input signal.

Generally, some current electrophysiology (EP) recording systems can effectively support the treatment of arrhythmias such as atrial flutter and supraventricular tachycardia, which show up as large-amplitude, low-frequency signals. However, more complex and prevalent arrhythmias, such as atrial fibrillation and ventricular tachycardia, which are characterized by low-amplitude, high-frequency signals, have not found an effective evaluation of all relevant signals.

This signal detection, acquisition, and isolation can be further complicated by equipment line noise and pacing signals. Current EP recorders use low-pass, high-pass, and notch filters to remove noise and artifacts from the various electrical signal information. Unfortunately, conventional filtering techniques can alter signals and make it difficult or impossible to see low-amplitude, high-frequency signals that can be inherent in cardiac monitoring, the visualization of which signals could help treat atrial fibrillation and ventricular tachycardia. It has been recently recognized that the assurance of waveform integrity, such as for the noise-free acquisition of IC and ECG signals in an EP environment, had not been previously accomplished due to contamination of various signals by artifacts and noise.

The patented PURE EP™ System can record raw (unaltered) cardiac and other physiologic signals with multiple display options, low noise, and a large input signal dynamic range. This is achieved using a low-noise amplifier topology with minimal filtering to band-limit the signal and a high-resolution A/D converter. In addition, the PURE EP™ System can provide large-signal (e.g., from a defibrillator) input protection and radio frequency (RF) signal (e.g., from ablation) noise suppression. There is no need for gain switching in this architecture, and the full range of input signals is digitized with high resolution.

“We are pleased to announce this newest patent allowance which demonstrates the clinical significance of our PURE EP™ System in filtering noise from complex signals in the EP setting,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.  “We believe we have the leading patent-protected solution for providing superior intracardiac signal information to electrophysiologists during catheter ablation procedures across all types of cardiac arrhythmias.”

One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

1 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119

Source: BioSig Technologies, Inc.

Avivagen Announces CEO Update to Shareholders

Posted on by Admin



Avivagen Announces CEO Update to Shareholders

Research, News, and Market Data on Avivagen

 

Ottawa, ON /Business Wire/ January 26, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces a CEO update to shareholders.

To our shareholders,

2021 was a year of challenge for all industries, with the global feed production industry no exception. With higher input costs that could not be passed along to consumers, ongoing COVID-19 pandemic concerns and worldwide supply chain challenges, many producers experienced financial difficulties and retrenchment, impacting every supplier they do business with – including Avivagen[i].

However, it appears that the environment is now becoming more favourable. After a period of delays numerous important Avivagen customers tell us they expect to ramp up activities in 2022. In turn, purchases of OxC-betaTM Livestock are anticipated to scale up, reaching volumes more in line with previous expectations. We’re seeing continued progress with trials and regulatory processes, and discussions with prospective customers, potential distribution partners and stakeholders worldwide are advancing.

We feel we are in the early days of resuming our growth plans and we are excited for what is on the horizon. Given developments in the broader market and within our Company, we feel now is a suitable time to provide and update on the recent progress that has been made and our outlook on the months and year ahead.

New leadership for a new stage of growth
As a part of our ongoing commitment to building the best possible team for the future of our business, we recently announced the appointment of Jamie Nickerson to the role of President, effective January 25, 2022. Jamie has been a core member of the Avivagen team for 15 years, most recently becoming the main contact with  many of our most important and lucrative relationships and developing new applications for our OxC-betaTM product as Vice President of Business Development and Innovation.  Few understand the Avivagen science, value proposition, market and business opportunity as completely as Jamie, making him the perfect individual to lead the next phase of growth for the Company.

This year we established important new relationships through our Mexico-based partner, Meyenberg International Group that will help spearhead expansion efforts in Central and South America. We also added Mr. Lesley Nernberg as a technical sales and marketing consultant with the goal of accelerating the adoption of OxC-betaTM Livestock in multiple Asian markets.

Strategic partnerships and regulatory milestones
This fall we announced a transformative supply agreement with AB Vista to expand marketing and sale of OxC-betaTM Livestock in high value markets such the United States, Brazil and Thailand. Trials with several AB Vista customers are already underway and we expect sales from this partnership to start and grow steadily throughout 2022. We also continue to seek similar strategic partnerships in additional major global feed markets.

We have continued our efforts to expand regulatory approval for use of our products and are expecting approvals for livestock use in both Vietnam and China over the coming months. In anticipation of these approvals, we have initiated discussions with both prospective customers and distributors in both markets.  Our previously announced distribution partner for Philippines, Inphilco, has successfully registered their own branded OxC-beta-based product and are beginning trials with several of its local customers. We are actively working towards new regulatory approvals in five key regions in South America and expect other regulatory developments for both companion animals (Vivamune) and humans.

Growing recognition from the scientific community
A recent analysis published in the Lancet, an international medical journal, reports that antibiotic resistance kills more than one million people each year– proving the critical need for safe and suitable alternatives to antibiotics[ii]. Concurrently, there has a marked increase in both the recognition and acceptance of our technology, due in part to a number of papers appearing in top-tier scientific publications – including several reaffirming the safety and utility of using OxC-betaTM Livestock as an alternative to antibiotics in broilers, sows and cows. These include:

  • Kang, M., Oh, J.Y., Cha, S.Y., Kim, W.I., Cho, H.S., Jang, H.K., 2018. Efficacy of polymers from spontaneous carotenoid oxidation in reducing necrotic enteritis in broilers. Poultry Sci. 97, 3058-3062 doi: 10.3382/ps/pey180.
  • Chen, J., Chen, J., Zhang, Y., Lv, Y., Qiao, H., Tian, M., Cheng, L., Chen, F., Zhang, S., Guan, W., 2020. Effects of maternal supplementation with fully oxidised ?-carotene on the reproductive performance and immune response of sows, as well as the growth performance of nursing piglets. Brit. J. Nutr., 1-9 doi: 10.1017/S0007114520002652.
  • Riley, W.W., Nickerson, J.G., Burton, G.W., 2021. Effect of Oxidized ?-Carotene on the Growth and Feed Efficiency of Broilers. Poultry Sci., 101088 doi: https://doi.org/10.1016/j.psj.2021.101088.
  • Burton, G.W., Mogg, T.J., Riley, W.W., Nickerson, J.G., 2021. Beta-Carotene oxidation products – Function and safety. Food Chem. Toxicol. 152, 112207 doi: 10.1016/j.fct.2021.112207.
  • Mogg, T.J., Burton, G.W., 2021. The ?-carotene–oxygen copolymer: its relationship to apocarotenoids and ?-carotene function. Can. J. Chem. 99, 751-762 doi: 10.1139/cjc-2021-0006.
  • McDougall, S., 2021. Evaluation of fully oxidised ?-carotene as a feed ingredient to reduce bacterial infection and somatic cell counts in pasture-fed cows with subclinical mastitis. N.Z. Vet. J., 1-9 doi: 10.1080/00480169.2021.1924091.

 

Positive customer developments signal opportunity in 2022 and beyond
A tough economic environment led many feed producers in markets worldwide to scale back in 2021, a reality that directly impacted our key relationships in Mexico in particular. However, customers such as Industrias Melder and Tranformadora appear to be entering 2022 on much stronger footing, meaning significant commercial agreements previously secured could resume shortly. Additionally, successful trials have been completed with large and well-known dairy and poultry producers in Mexico which we expect should result in new orders placed within the coming weeks. We have also secured a number of smaller but important agreements in Asia that will diversify our customer base and product applications over the coming years. In the companion animal space, our Vivamune dog chews have been successfully introduced in Taiwan and our OxC-beta product is being used as a cornerstone ingredient in a premium dog food brand.

A new look for Avivagen
Our recently relaunched website could be seen as a marker for the next phase of Avivagen as a company, as we build off of the foundational success achieved to date and enter a period of new leadership and growth over the coming months and years. We have seen early success in numerous key markets, and with growing recognition from the scientific community and regulatory authorities we believe Avivagen is poised to grow that number. We have established important and lucrative relationships in many of the largest feed-producing markets in the world and secured expert support to help us develop new relationships that will enable growth in our livestock, companion animal and human nutrition businesses.

After two years of global uncertainty there are brighter and healthier days on the horizon.

None of this would be possible without the partnership and support of our shareholders. I thank you for your continued confidence in Avivagen, its leadership and its vision as we move into the next phase of growth.

Sincerely,

Kym Anthony
Chief Executive Officer

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven thatproduct performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to Avivagen’s expectation that customers will ramp up activities in 2022, expected growth in demand and orders for Avivagen’s products, the timing, outcomes and potential benefits of trials and regulatory processes underway, the potential for regulatory approval in additional jurisdictions, the expectations that current partner and customer discussions will result in agreements and orders that are beneficial to Avivagen, the expected resumption of orders and shipments to customers in Mexico, Avivagen’s ability to diversify its customer base in the future and the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the industry and Avivagen’s customers may not rebound as quickly as expected, COVID or another event outside their control could impact customer and partner buying decisions, demand may not increase or stay at the same levels for Avivagen products, trials may not be completed or the results of trials may not result in benefits to Avivagen, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

 

[ii] The Financial Times, January, 2022  Antibiotic resistance kills over 1m people a year says study _ Financial Times.pdf

Aurania Provides Update On Operations

Posted on by Admin



Aurania Provides Update On Operations

Research, News, and Market Data on Aurania Resources

 

Toronto, Ontario, January 26, 2022 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) provides an update on its operations and announces a temporary suspension of most activities at its Lost Cities-Cutucu project in southeastern Ecuador as a result of recent COVID-19 guidelines.

There are currently 9 active COVID cases among our personnel and our General Manager is in quarantine because a family member is infected. Ecuador is beginning to experience an increase in the number of cases nationwide, and on January 16th a “Red Alert” was issued by the Ecuador Government for 193 of 195 Cantons.  We are required under Ecuadorian law to follow the guidelines imposed by the Ministry of Health and the Ministry of Labour and the protocols that we were required to submit to the Government last year.  Because the Omicron Variant appears to be much more transmissible than any other COVID variant to date, we are taking the decision to suspend the majority of our field activities more or less over the next month in order to protect our employees and the local communities in which we operate.  Where possible we may continue field work with a reduced contingent in those remote areas where there is no interaction with local communities.

Laboratory analyses have been received from hole TSN1-009 at Tsenken, designed to sample the contact of a “salt wall” lying along a prominent fault structure.  Such sites have historically yielded abundant copper from projects in Peru and so the drill hole was meant to test an analogous geological setting.  The hole collapsed due to caving in salt at a downhole depth of 369 metres.  It was projected to intersect the target area at 400-500 metres.  Low anomalous copper and silver were returned from a 9-metre interval downhole at 321 to 331 metres.  Within this intersection breccia clasts containing chalcocite, a copper sulphide, were noted.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”)

Laboratories: The samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.

Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% copper, zinc and lead, and 100g/t silver, 0.4 grams of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been reviewed and approved by Jean-Paul Pallier, MSc. Mr. Pallier is a designated EurGeol by the European Federation of Geologists and is a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Sierra Metals (SMTS)(SMT:CA) – Darkest Before The Dawn

Posted on by Admin

Wednesday, January 26, 2022

Sierra Metals (SMTS)(SMT:CA)
Darkest Before The Dawn

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Fourth quarter and full year 2021 production. During the fourth quarter, Sierra Metals produced 6.1 million pounds of copper, 6.0 million pounds of lead, 14.9 million pounds of zinc, 1.9 thousand ounces of gold, and 805 thousand ounces of silver. Compared with the prior year period, fourth quarter production of copper, lead, zinc, gold, and silver declined 42.9%, 21.2%, 31.0%, 44.6%, and 12.7%, respectively, and declined 26.5%, 23.3%, 22.0%, 17.6%, and 0.2% sequentially. The quarter reflected operational challenges, and while Cusi and Yauricocha are approaching normalized operations, infill drilling and mine development is needed at Bolivar to normalize operations by the end of the second quarter. Compared to 2020, full year silver production increased 1.8%, while copper, lead, zinc, and gold production declined 28.3%, 6.5%, 3.2%, and 30.5%, respectively.

    Updating estimates.  We are lowering our 2021 EPS and EBITDA estimates to $0.06 and $89.7 million from $0.13 and $105.7 million, respectively, to reflect lower production. We also lowered our 2022 EPS and EBITDA estimates to $0.22 and $121.8 million from $0.36 and $163.2 million, respectively, which reflects a steady improvement in operating performance that is back-end loaded. Our preliminary 2023 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Capstone Green Energy (CGRN) – New contract keeps Capstone on track to meet rental goal. Example of more to come?

Posted on by Admin

Wednesday, January 26, 2022

Capstone Green Energy (CGRN)
New contract keeps Capstone on track to meet rental goal. Example of more to come?

Capstone Green Energy Corp is the producer of low-emission microturbine systems.The company develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation applications. Capstone Turbine’s products include onboard generation for hybrid electric vehicles; conversion of oil field and biomass waste gases into electricity; combined heat, power, and chilling solutions; capacity addition; and standby power.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Capstone signed a 4 MW two-year, EAAS contract with a new customer in the cryptocurrency space. Recall that Capstone is moving toward increased Energy As A Service (EAAS) sales and is seeking to increase equipment rentals to 21 megawatts by this spring from a September level of 13.1 MW. Today’s announcement places the company on track to meet its goal.

    The new customer is in a fast growing space that plays off of Capstone’s experience with exploration and production companies.  The customer is located on an oil and gas well and will use waste gas emissions to perform large volume, blockchain and cryptocurrency mining. Capstone has a history of serving exploration and production customers. We believe the use of small generators using gas waste to …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Avivagen Announces Appointment of James Nickerson as President

Posted on by Admin



Avivagen Announces Appointment of James Nickerson as President

Research, News, and Market Data on Avivagen

 

Ottawa, ON /Business Wire/ January 25, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is excited to announce the appointment of James  (“Jamie”) Nickerson, PhD as President of Avivagen. The appointment will be effective immediately.

“Jamie has been one of the most important members of Avivagen since the early days of the organization. His impressive track record contributing to both the science behind our offerings, as well as the growth of the business surrounding them, makes him the perfect individual to lead the next phase of growth for our company,” says Kym Anthony, Chief Executive Officer of Avivagen. “I look forward to working closely with Jamie as he establishes himself in the role and assumes leadership of Avivagen during this exciting and important stage of the company’s success.”

Currently Mr. Nickerson holds the role of Vice President of Business Development and Innovation for Avivagen. In this role he has been crucial in identifying and establishing a number of the strategic and  important customer and distribution partner relationships that are core to Avivagen’s ongoing growth and global expansion. He has also been central in finding new applications for the company’s OxC-beta™  product in both the animal and human nutrition fields.

Upon joining Avivagen in 2007, Mr. Nickerson established Avivagen’s Charlottetown biological research facility and directed the research and development program as senior research biologist. Over the next 15 years he held progressively senior roles within the company, including Director of Biology and Director of Commercialization Science, prior to taking over Business Development and Innovation responsibilities. During this period he also co-authored six scientific papers on Avivagen’s oxidized carotenoid technology platform, and is listed as an author on seven patents relating to the company’s product.

“I’ve been proud to be a part of the Avivagen journey for the past 15 years and am very excited to have the opportunity to lead this exciting next phase of the company,” said Mr. Nickerson. “We have laid the foundation to become an important global player in the future of both animal and human nutrition at a time when antibiotic effectiveness is waning in both areas. There is a bright future ahead for Avivagen, and I look forward to working closely with our team, our customers, our partners and our shareholders to take full advantage of the opportunities at hand.”

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to the future growth and prospects for Avivagen and the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

A Visit To Aurania’s Lost Cities Project With Prof. Gregor Borg: Part 3

Posted on by Admin



A Visit To Aurania’s Lost Cities Project With Prof. Gregor Borg: Part 3

Research, News, and Market Data on Aurania Resources

 

Independent consultant, Dr. Gregor Borg provides feedback following his recent visit to Aurania’s Lost Cities – Cutucu project in southeastern Ecuador.  Professor Borg has completed three site visits to date.

In Part 3 of this interview-style video, Professor Borg discusses the presence of salt in the Cutucu Basin.

Indonesia Energy To Commence Drilling of Two Back-To-Back New Wells Within 30 Days and a Third by Mid-Year

Posted on by Admin



Indonesia Energy To Commence Drilling of Two Back-To-Back New Wells Within 30 Days and a Third by Mid-Year

Research, News, and Market Data on Indonesia Energy

 

New Production Anticipated to Bring IEC to Cash Flow Positive Operations

JAKARTA, INDONESIA and DANVILLE, CA / ACCESSWIRE / January 26, 2022 / Indonesia Energy Corporation Limited (NYSE American:INDO) (IEC), an oil and gas exploration and production company focused on Indonesia, today provided an update on its 2022 drilling plans by announcing that it expects to commence drilling of its next two (2) new wells at IEC’s 63,000-acre Kruh Block within 30 days. Additionally; IEC plans to commence drilling of a third new well at Kruh Block before the end of the second quarter.

Drilling operations for these three new wells (named “Kruh 27”, “Kruh 28” and “Kruh 29”) are being funded from the net proceeds of IEC’s recently announced new institutional investor financing.

Last month, IEC announced that its recently completed “Kruh 26” well increased its daily oil production rate by over 50%.

Assuming the drilling campaigns for Kruh 27 and Kruh 28 yield producing wells, IEC’s production target is to be producing approximately 450 barrels of oils per day after completion of Kruh 27 and Kruh 28. Based on current oil prices, this production is anticipated to result in IEC having cash flow positive operations. The addition of a producing Kruh 29 well would enhance IEC’s cash flow from operations later this year.

The new wells will cost approximately $1.5 million each to drill and complete (matching IEC’s planned drilling budget). Based on the terms of IEC’s contract with the Indonesian government and an assumed oil price of $80 per barrel, these wells are each expected to generate approximately $1.5 million in net revenue in their first year, which is enough to recover the cost of drilling the wells.

Mr. Frank Ingriselli, IEC’s President, commented “We are excited that our recent financing enables us to commence drilling next month and to aggressively move our company towards a potential cash flow positive position, setting the stage for further drilling and growth for our company in 2022 and beyond. We believe Kruh Block is a world class asset that should significantly grow our cash flow as we drill additional wells and seek to maximize returns on our investments and grow shareholder value.”

About Indonesia Energy Corporation Limited
Indonesia Energy Corporation Limited (NYSE American:INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements
All statements in this press release of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, when used in the preceding discussion, the words “estimates,” “believes,” “hopes,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results (including, without limitation, the future prices for oil and the anticipated results of IEC’s drilling and production activities and the impact of such activities on IEC’s results of operations as descried herein) to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2020, filed on May 18, 2021, with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:
Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com

SOURCE: Indonesia Energy Corporation Limited

Eagle Bulk Shipping (EGLE) – Well Positioned For 2022

Posted on by Admin

Wednesday, January 26, 2022

Eagle Bulk Shipping (EGLE)
Well Positioned For 2022

Eagle Bulk Shipping Inc. is a US-based drybulk owner-operator focused on the Supramax/Ultramax mid-size asset class, which ranges from 50,000 and 65,000 deadweight tons in size; these vessels are equipped with onboard cranes allowing for the self-loading and unloading of cargoes, a feature which distinguishes them from the larger classes of drybulk vessels and provides for greatly enhanced flexibility and versatility- both with respect to cargo diversity and port accessibility. The Company transports a broad range of major and minor bulk cargoes around the world, including coal, grain, ore, pet coke, cement, and fertilizer. Eagle operates out of three offices, Stamford (headquarters), Singapore, and Hamburg, and performs all aspects of vessel management in-house including: commercial, operational, technical, and strategic.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Favorable Dry Bulk Market Outlook Intact, Albeit with Volatility. While overall TCE rates have dropped recently due to weather disruptions and seasonality and the forward cover is low, the outlook remains favorable. Volatility is likely to continue, and seasonality should be expected. At the same time, the order book remains muted, and the January 1, 2023 implementation of new carbon emission regulations (EEXI) could trigger slow steaming that effectively lowers supply.

    Well Positioned Entering 2022.  Several milestones were achieved over the past five years and the moves enhanced the competitive position moving into this year. The fleet renewal program improved the fleet profile, the commercial strategy has consistently outperformed the market, the capital structure has been simplified with a global refinancing in 4Q2021, access to equity capital markets has …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Aurania Provides Update On Operations

Posted on by Admin



Aurania Provides Update On Operations

Research, News, and Market Data on Aurania Resources

 

Toronto, Ontario, January 26, 2022 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) provides an update on its operations and announces a temporary suspension of most activities at its Lost Cities-Cutucu project in southeastern Ecuador as a result of recent COVID-19 guidelines.

There are currently 9 active COVID cases among our personnel and our General Manager is in quarantine because a family member is infected. Ecuador is beginning to experience an increase in the number of cases nationwide, and on January 16th a “Red Alert” was issued by the Ecuador Government for 193 of 195 Cantons.  We are required under Ecuadorian law to follow the guidelines imposed by the Ministry of Health and the Ministry of Labour and the protocols that we were required to submit to the Government last year.  Because the Omicron Variant appears to be much more transmissible than any other COVID variant to date, we are taking the decision to suspend the majority of our field activities more or less over the next month in order to protect our employees and the local communities in which we operate.  Where possible we may continue field work with a reduced contingent in those remote areas where there is no interaction with local communities.

Laboratory analyses have been received from hole TSN1-009 at Tsenken, designed to sample the contact of a “salt wall” lying along a prominent fault structure.  Such sites have historically yielded abundant copper from projects in Peru and so the drill hole was meant to test an analogous geological setting.  The hole collapsed due to caving in salt at a downhole depth of 369 metres.  It was projected to intersect the target area at 400-500 metres.  Low anomalous copper and silver were returned from a 9-metre interval downhole at 321 to 331 metres.  Within this intersection breccia clasts containing chalcocite, a copper sulphide, were noted.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”)

Laboratories: The samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.

Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% copper, zinc and lead, and 100g/t silver, 0.4 grams of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been reviewed and approved by Jean-Paul Pallier, MSc. Mr. Pallier is a designated EurGeol by the European Federation of Geologists and is a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Michael Burrys Interesting Half Dozen Public Equity Holdings

Posted on by Admin 


	Image Credit: Patrick Feller (Flickr)


Michael Burry’s Investments in Health, Bombs, and Bars

 

Michael Burry’s investing genius was brought to the world’s attention in the movie The Big Short. When the hedge fund manager’s insight and brilliance became known, investors made a practice of checking the latest transactions from his company, Scion Capital Management, on its 13F quarterly filing. His latest filing shows that he scaled down his stock holdings considerably. In fact, when compared to the previous quarter, Burry’s holdings of public companies went from 22 to just 6. 

It’s safe to say Burry’s investment universe is broader than the average self-directed investor and even deeper than the average hedge fund manager.  With this in mind, out of the entire universe of publicly held corporations he could hold, there are only six that Burry’s portfolio owned at the end of the third quarter. Of the six, two are large-cap household names, and the others have smaller market-caps and are far less known. It’s on the lesser-known opportunities that we’ll focus.

 

SCION ASSET MANAGEMENT, LLC – Q3 2021 (per 13F filing)

Sources: Whale Wisdom / Channelchek

 

The two large-cap names, CVS Health (CVS) and Lockheed Martin (LMT) shouldn’t need an introduction. CVS operates retail and mail-order pharmacies. Lockheed Martin is a defense contractor that builds military satellites, missile control systems, mission systems, and aeronautics. As for the four smaller companies, there are two prison systems, a health care company, and a distributor of oil and gas services. These are the four out of the thousands of publicly traded stocks available to Dr. Michael Burry that we will explore further.

Burry’s Small-Cap and Microcap Holdings

CoreCivic (CXW) is a company that owns and manages private prisons and detention centers along with related concessions. CoreCivic is a publicly owned prison system that was trading as a REIT up until January 2021, it now trades as a Regular C-Corporation.

In a research report dated January 11, 2022, titled A
Significant Win Noble Capital Markets Senior Research Analyst, Joe Gomes we learn that CoreCivic is one of the largest private owners of real estate used by U.S. government agencies.  The Company owns 15 properties representing nearly 2.7 million square feet of real estate, all used by government agencies. 

Shortly after being inaugurated, President Biden signed an executive order directing the attorney general to not renew Justice Department contracts with privately operated criminal detention facilities.  The company has been proactive in pivoting to adjust to the changing operating landscape. The company’s initial steps are discussed in an exclusive Channelchek
Virtual Roadshow.  

CoreCivic’s 52-week price range is $5.92-$12.35.

 

NOW Inc. (DNOW) is a global distributor to the oil and gas markets. It does business under the brands DistributionNOW and DNOW. The Company operates approximately 130 locations in the U.S., and 40 locations in Canada, plus nearly 20 other countries. NOW’s energy product offerings are used in the oil and gas industry, including upstream drilling and completion, exploration and production, midstream infrastructure development, and downstream petroleum refining. They also operate in related industries such as chemical processing, power generation, and industrial manufacturing operations. NOW provides supply chain management to drilling contractors, E&P operators, midstream operators, downstream energy, and industrial manufacturing companies.

DNOW’s 52-week price range is $6.83-$11.98.

GEOGroup (GEO) is another correctional facility play that specializes in the ownership, leasing, and management of correctional, detention, and reentry facilities as well as community-based services and youth services in the United States, Australia, South Africa and the United Kingdom. The Company owns, leases and operates a range of secure facilities, including maximum, medium, and minimum-security facilities, processing centers, as well as community-based reentry facilities. It also offers delivery of offender rehabilitation services under its GEO Continuum of Care platform.

In a research report dated January 11, 2022, titled What Do The
Debt Negotiations Reveal?, Noble Capital Markets Senior Research Analyst Joe Gomes updates investors on the company including a section on GEO’s monitoring business called BI. The analysts calls BI “a hidden gem.” Gomes explains GEO is a market leader in the monitoring business with over 2,000 active contracts and a 98% customer retention rate.  He presents the value this way, “BI is the largest producer of electronic monitoring devices and has developed an unrivaled platform of monitoring, case management, and supervisory services. Since 2015, BI has generated a 12% CAGR in revenue and should end 2021 with about $260 million of revenue. With many clients seeking an alternative to detention for low-risk offenders, we believe there remains substantial growth potential in this business.”

GEO’s 52-week price range is $4.96-$11.

 

SCYNEXIS Inc. (SCYX) is a drug development company focusing on the commercialization of novel anti-infectives to address what they see as a significant amount of unmet therapeutic needs. The company engages in developing a lead product candidate, SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. According to information found under the company ticker on Channelchek, it is a structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS’ 52-week price range is $4.21-$10.25.

Take-Away

Dr. Burry has an excellent record of spotting investment opportunities before the rest of the market catches up. His picks are as disparate as the mortgage market in 2008 and GameStop (GME) in 2020. Burry will typically see what others are not looking at. One-third of his public company holdings are prison and detention center related. Does he believe the industry is beaten up and will rise, does he think the real estate or other assets owned are valuable beyond the stock price, perhaps something else? The research reports for both CXW and GEO may provide more insight.

One of his other two small company holdings, DNOW, is an oil and gas distributor. This is another industry that would appear to have substantial government policy headwinds. The last, SCYX, develops drugs to fight off fungus infections. It is a microcap company that is the smallest of the six that Burry committed capital to.

 Paul Hoffman

Managing Editor, Channelchek

Suggested Content



CoreCivic C-Suite Interview (Video)

Biden Signs Executive Order to End Use of Private Prisons by BoP





Michael Burry vs Cathie Wood is Not an Even Competition

Is the Index Bubble Michael Burry Warned About Still Looming?

 

Sources

https://whalewisdom.com/filer/scion-asset-management-llc#

https://www.youtube.com/watch?v=URBOifP8EDY

https://channelchek.com/news-channel/Wall_Streets_Tools_to_Copycat_Meme_Stock_Investor_Successes

 

Stay up to date. Follow us:

 

Schwazze Closes Acquisition Of Drift

Posted on by Admin



Schwazze Closes Acquisition Of Drift

Research, News, and Market Data on Schwazze

 

Expanding Retail Footprint in Boulder County, Colorado

OTCQX: SHWZ

DENVER, Jan. 26, 2022 /CNW/ – Schwazze, (OTCQX:SHWZ) (“Schwazze” or the “Company”), is pleased to announce that it has closed the transaction to acquire the assets of BG3 Investments, LLC dba Drift which consists of two cannabis dispensaries located in Boulder, Colorado. This purchase continues Schwazze’s expansion plan in Colorado, adding to the Company’s current dispensary footprint, and bringing the total number of dispensaries to twenty. As part of the purchase, Schwazze will also acquire the assets of Black Box Licensing, LLC, which contains certain intellectual property.

“We look forward to adding these dispensaries to our portfolio. The Company remains focused on bringing excellent shopping experiences to all areas of Colorado by providing a wide assortment of quality products along with great service that our customers have come to expect from our brands.  We are excited to bring that experience to our customers in Boulder,” said Nirup Krishnamurthy, Schwazze’s COO.

The consideration for the acquisition was $3.5 million and was paid as $1.9 million in cash, and $1.6 million in common stock.

Corporate Update
Since April 2020, Schwazze has announced and/or acquired a total of 32 cannabis dispensaries, including the ten R. Greenleaf New Mexico dispensaries.  The Company has also announced and/or acquired in 2021 a total of seven cultivation facilities, three in Colorado – SCG Holding LLC, Brow 2 LLC and Star Buds – and four licensed by Medzen and RGO in New Mexico.  The R. Greenleaf acquisition will add a New Mexico manufacturing asset, Elemental Kitchen & Laboratories, LLC, to the Company’s manufacturing plant, Purplebee’s in Colorado.

In May 2021, Schwazze announced its BioSciences division and in August 2021 it commenced home delivery services in Colorado.

About Schwazze 
Schwazze (OTCQX: SHWZ) is building a premier vertically integrated regional cannabis company with assets in  Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position.  Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.  The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition.  Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes.  The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.  Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.  Medicine Man Technologies, Inc. was Schwazze’s former operating trade name.  The corporate entity continues to be named Medicine Man Technologies, Inc.

Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “estimates”, “predicts,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the actual revenues derived from the Company’s Star Buds assets, * the Company’s actual revenue and adjusted EBITDA for 2021, (xi) the Company’s ability to generate positive cash flow for the rest of 2021 (xii) the ongoing COVID-19 pandemic, (xiii) the timing and extent of governmental stimulus programs, and (xiv) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Schwazze